101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Market cap: $47.8M (2/11/2026)
Price: $2.43
Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
Webinar January 28, 2026 Presenter: Maria Maccecchini, Ph.D., President and CEO
Earnings Release
Annovis Bio, Inc. Enters $3.425 Million Registered Direct Offering
Announces $6 Million Registered Direct Offering of Common Stock
Appoints Mark Guerin as Chief Financial Officer
News
Provides Corporate Updates and Reports
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Free Writing Prospectus
S-1MEF